Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: The Company manufactures and distributes apparatus, instruments, devices, and consumables for life science research and regenerative medicine. The reporting period reflects the impact of recent acquisitions (Denville Scientific and Coulbourn Instruments) and a significant non-cash income tax benefit.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Revenues | $26,453 | $78,658 |
| Gross Profit | $12,567 | $37,399 |
| Gross Margin % | 47.5% | 47.5% |
| Operating Income | $1,943 | $7,290 |
| Net Income | $12,730 | $16,832 |
| Diluted EPS | $0.44 | $0.57 |
| Cash and Equivalents (Sep 30, 2010) | $17,217 | |
| Total Debt (Outstanding) | $18,009 | |
| Net Cash Provided by Operating Activities (9mo) | $8,044 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 26.0% ($5.5M) for the quarter and 35.3% ($20.6M) for the nine months compared to the prior year. This growth was primarily driven by the acquisitions of Denville Scientific and Coulbourn Instruments, which contributed approximately $5.2M and $17.4M respectively to the revenue increases. Organic growth was reported at 4.6% for the quarter and 6.5% for the nine months.
- Net Income Surge: Net income for the quarter increased from $1.3M to $12.7M. This dramatic increase is largely attributable to a discrete income tax benefit of approximately $11.3M resulting from the release of valuation allowances on U.S. deferred tax assets, based on management's conclusion that these assets are now more likely than not to be realized.
- Gross Margin Compression: Gross margin percentage decreased to 47.5% from 48.7% (quarterly) and 49.2% (nine-month) in the prior year. Management attributes this to the lower gross margins of Denville Scientific, which distributes rather than manufactures products. Excluding Denville, margins improved.
- Operating Expenses: Sales and marketing expenses increased significantly (44.6% quarterly) due to acquired subsidiary costs and expanded marketing efforts. Restructuring charges of $0.3M were recorded in Q3 2010 related to workforce reductions at the Panlab (Spain) facility.
Guidance, Outlook, and Risks
- Product Launches: The Company launched new research syringe pumps (Pump 11 Elite and KDS 100 Legato) and an upgraded spectrophotometer platform, expecting these to drive organic growth. They are also developing tools for regenerative medicine, including bioreactors and clinical injectors, with a target launch for a clinical product in 2011.
- Microvolume Spectrophotometer Risk: A key distributor has a contractual right to earn exclusivity on the microvolume spectrophotometer by meeting purchase minimums in 2010. The Company expects sales of this product to the distributor to be significantly lower in 2011 due to high inventory levels at year-end 2010. Management is developing strategies to offset this potential revenue decline.
- Liquidity and Capital: The Company has a $20.0M revolving credit facility with $18.0M outstanding as of September 30, 2010, leaving $2.0M available. Management expects current cash, operating cash flow, and debt capacity to be sufficient for operations for at least 12 months. However, additional capital may be required for significant acquisitions.
- Foreign Currency: A stronger U.S. dollar negatively impacted revenues by $0.7M in the quarter and nine months. The Company remains exposed to fluctuations in the British pound and Euro.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the assumptions behind the $11.3M tax benefit and the likelihood of realizing the released deferred tax assets in future periods.
- 2011 Revenue Outlook: Assess the Company's specific plans to offset the anticipated drop in microvolume spectrophotometer sales to the key distributor in 2011.
- Debt Covenants: Confirm continued compliance with the credit facility covenants (income, debt coverage, working capital) given the high utilization of the $20M line.
- Acquisition Integration: Monitor the integration progress and margin performance of Denville Scientific and Coulbourn Instruments to ensure they meet accretive expectations.
- Regenerative Medicine Pipeline: Track the regulatory approval timeline for the clinical syringe pump and commercial adoption of the bioreactor products.